AI assistant
Cryoport, Inc. — Director's Dealing 2024
Mar 20, 2024
32876_dirs_2024-03-19_0999f288-93d9-43e1-bbd7-21a49a5e0898.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cryoport, Inc. (CYRX)
CIK: 0001124524
Period of Report: 2024-03-09
Reporting Person: SHELTON JERRELL (Director, President, CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-09 | Common Stock | M | 8250 | — | Acquired | 640674 | Direct |
| 2024-03-11 | Common Stock | S | 3723 | $16.3524 | Disposed | 636951 | Direct |
| 2024-03-15 | Common Stock | S | 2599 | $20.789 | Disposed | 634352 | Direct |
| 2024-03-15 | Common Stock | A | 14901 | — | Acquired | 649253 | Direct |
| 2024-03-15 | Common Stock | M | 100000 | $4.80 | Acquired | 749253 | Direct |
| 2024-03-15 | Common Stock | S | 54440 | $15.0414 | Disposed | 694813 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-09 | Restricted Stock Rights | $ | M | 8250 | Disposed | Common Stock (8250) | Direct | |
| 2024-03-15 | Stock Option (right to buy) | $4.80 | M | 100000 | Disposed | 2024-12-18 | Common Stock (100000) | Direct |
| 2024-03-15 | Stock Option (right to buy) | $16.70 | A | 33524 | Acquired | 2031-03-15 | Common Stock (33524) | Direct |
Footnotes
F1: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock.
F2: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
F3: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025.
F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.84 to $15.28, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024.
F6: 1/48 of the options vested on the 18th of each month for forty-eight months beginning on January 18, 2015.
F7: 1/48 of options vest on the 15th of each month for forty-eight months beginning April 25, 2024.